Abciximab prevents ischemic complications during angioplasty

Matthew T. Roe, David J. Moliterno

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


The EPILOG trial showed that the platelet glycoprotein IIb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, without increasing the risk of hemorrhage.

Original languageEnglish
Pages (from-to)267-272
Number of pages6
JournalCleveland Clinic Journal of Medicine
Issue number5
StatePublished - May 1998

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Abciximab prevents ischemic complications during angioplasty'. Together they form a unique fingerprint.

Cite this